ACTRN12620001349932尚未招募4 期
Acute Haemodynamic Study of Mirabegron in Pulmonary Arterial Hypertension: Effect on Pulmonary Vascular Resistance
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 19 Years 至 80 Years（—）
- 性别
- All
入选标准
- •We will enrol patients with a diagnosis of PH that fulfil all of the following criteria:
- •A- PH due to following aetiologies/diagnostic classifications:
- •- Group 1 pulmonary hypertension
- •- Chronic pulmonary hypertension due to inoperable small distal pulmonary emboli (also known as CTEPH
- •B-The patient is:
- •-PH treatment naïve or,
- •-on an endothelin receptor antagonist (ERA) (Bosentan, Macitentan or Ambrisentan) as monotherapy, or,
- •-on combination therapy with an ERA (Bosentan, Macitentan or Ambrisentan) plus an agent in the NO pathway (Sildenafil, Tadalafil or Riociguat) when the NO-related therapy can be safely withheld in short-term
- •C-The right heart catheterisation is clinically indicated.
- •D- The participant does not meet any of the exclusion criteria
排除标准
- •Significant hepatic (transaminases or bilirubin x 3 above upper reference level) or renal impairment (GFR< 30 ml/min/1,73 m2).
- •Significant hypotension (defined as symptomatic systolic blood pressure < 80 mmHg) or hypertension (defined as systolic >180 mmHg and/or diastolic blood pressure >110 mmHg).
- •Right heart failure defined with PH associated with systemic venous congestion and fluid retention (e.g. peripheral oedema, ascites)
- •Left heart failure (LVEF <50% and clinical signs of left heart failure).
- •Severe interstitial lung disease with forced vital capacity (FVC) < 70%
- •Congenital or drug-induced QT prolongation.
- •Patients with known bladder outlet obstruction and patients taking antimuscarinic medications for overactive bladder syndrome.
- •Anaemic patients with Hb <100 mg/dL and iron deficiency or gastrointestinal bleed within 6 months.
- •Treatment with a tricyclic antidepressant or CYP2D6 substrates other than beta-blockers or treatment with digoxin.
- •Pregnancy in female participants : female subjects of childbearing potential must have a pregnancy test performed with negative results known within 7 days prior to the index procedure.
- •Breast feeding in female participants: female subject is not breastfeeding at the time of the screening visit and will not be breast-feeding at the time of the study.
- •Subject has participated in another study during the 30 days preceding the current study.
- •Hypersensitivity(allergic reaction) to inhaled nitric oxide
- •Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy.This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, members of the armed forces, and persons kept in detention.
研究者
相似试验
已完成
不适用
The hemodynamic and pulmonary effects of acute high altitude exposure at rest and during exercise in patients with complex congenital heart diseasescongenital heart disease10010394NL-OMON46314niversitair Medisch Centrum Utrecht60
招募中
2 期
Haemodynamic effects of Milrinone in patients with heart failure and preserved ejection fraction (HFPEF)Cardiovascular - Other cardiovascular diseasesHeart failureACTRN12614000727640Alfred Health14
招募中
不适用
Comparison of pregabalin and fentanyl after endotracheal intubatioAcute pain.Other acute postprocedural painG89.18IRCT20111010007752N12Babol University of Medical Sciences64
进行中（未招募）
1 期
Effects of the drug Benzbromaron on the pulmonary vesselsPulmonary arterial hypertensionEUCTR2015-000709-38-ATMedical University of Graz
已完成
不适用
Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasiaOveractive bladderJPRN-UMIN000019735Department of Urology, Shiga University of medical Science20